Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The role of transplantation in Ph+ ALL patients treated with chemotherapy-free regimens

In this video, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the role of transplantation in patients with newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) treated with ponatinib and blinatumomab. Dr Short highlights how the treatment of patients may shift away from transplant and focus on chemotherapy-free regimens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

N.J.S. reports receiving research grants from Takeda Oncology, Astellas Pharma Inc., Stemline Therapeutics, Inc, and Xencor and has received honoraria from Amgen, Jazz Pharmaceuticals, Astellas Pharmac, Inc., Novartis and Pfizer.